Targeting therapy to NSD2, the oncogene deregulated by t(4;14) in multiple myeloma

By understanding the biology of t(4;14) multiple myeloma, which makes up 15% of newly diagnosed myeloma and constitutes a disproportionately high percentage of aggressive disease, we will be able to effectively target these high-risk cases. The oncogene NSD2 is exclusively overexpressed in this subtype of disease and is present in all of the clonal cancer cells making it an excellent target for therapy. This project will specifically explore the function and biology of NSD2 and how it can be effectively targeted in the clinic. Gareth J Morgan, M.D. Ph.D, the Director for Myeloma research at the NYU Langone Health’s Perlmutter Cancer Center (NYU Langone), will serve as the Site Principal Investigator (SPI) at NYU Langone Health. Dr. Morgan’ research has successfully focused on the biology and treatment of myeloma and related plasma cell dyscrasias. He is particularly interested in the identification and treatment of patients with high-risk disease and has explored the genetic drivers underlying progression of myeloma to high-risk disease states, risk stratification approaches and risk-adapted treatment strategies.

Gareth Morgan, MD, PhD headshot

Gareth Morgan, MD, PhD

Professor of Medicine and Director Myeloma Research
NYU Grossman School of Medicine
Perlmutter Cancer Center
NYU Langone Health

NYU Langone Health logo